Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

被引：0
|
作者：
Ip, H. N. N. [1 ]
Hwang, I. [2 ]
Kang, J. [2 ]
Kim, K-P. [2 ]
Jeong, J. H. [2 ]
Chang, H-M. [2 ]
Ryoo, B-Y. [2 ]
Yoo, C. [2 ]
机构：
[1] Chinese Univ Hong Kong, Med, Hong Kong, Peoples R China
[2] Asan Med Ctr, Oncol, Seoul, South Korea
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
193P
引用
收藏
页码：61 / 61
页数：1
相关论文
共 50 条
  • [31] Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
    Hwang, Inhwang
    Kang, Jihoon
    Yoo, Changhoon
    Kim, Kyu-Pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [32] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [33] Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis
    Lee, K.
    Hwang, I.
    Kang, J.
    Yoo, C.
    Kim, K-P.
    Jeong, J. H.
    Chang, H-M.
    Ryoo, B-Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [34] Neutrophil to lymphocyte ratio is a predictor of outcome in metastatic pancreatic cancer patients (MPC) treated with nab-paclitaxel and gemcitabine
    Ventriglia, J.
    Petrillo, A.
    Huerta, M.
    Laterza, M. M.
    Savastano, B.
    Gambardella, V.
    Tirino, G.
    Pompella, L.
    Diana, A.
    Febbraro, A.
    Troiani, T.
    Orditura, M.
    Cervantes, A.
    Ciardiello, F.
    De Vita, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [35] Gemcitabine plus nab-paclitaxel as second line and beyond for metastatic pancreatic cancer (MPC): A single institution retrospective analysis
    Zaniboni, Alberto
    Bertocchi, Paola
    Abeni, Chiara
    Ogliosi, Chiara
    Rizzi, Anna
    Rota, Luigina
    Di Blasi, Brunelle
    Prochllo, Tiziana
    Aroldl, Francesca
    Meriggi, Fausto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [36] Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
    You, Min Su
    Ryu, Ji Kon
    Choi, Young Hoon
    Choi, Jin Ho
    Huh, Gunn
    Paik, Woo Hyun
    Lee, Sang Hyub
    Kim, Yong-Tae
    GUT AND LIVER, 2018, 12 (06) : 728 - 735
  • [37] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Lei Yang
    Jing Su
    Wenbo Wang
    Fuxiang Zhou
    World Journal of Surgical Oncology, 21
  • [38] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Yang, Lei
    Su, Jing
    Wang, Wenbo
    Zhou, Fuxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [39] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345